trending Market Intelligence /marketintelligence/en/news-insights/trending/3oS5TpkP7l6AeYILwzJSKA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Taro Pharmaceuticals recalls 1 lot of epilepsy drug due to cross-contamination

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Taro Pharmaceuticals recalls 1 lot of epilepsy drug due to cross-contamination

Taro Pharmaceuticals U.S.A. Inc. initiated a voluntarily recall of one lot of lamotrigine 100-milligram tablets due to cross-contamination with another drug at the manufacturing facility.

The medication is indicated for the treatment of epilepsy and bipolar disorder.

According to a Jan. 10 news release, tablets in the lot were found to have been cross-contaminated with a small amount of another drug substance called enalapril maleate.

The Hawthorne, N.Y.-based private pharmaceutical company said it did not receive any product complaints or adverse events regarding the recalled tablets.

The company said it is notifying distributors and arranging for the return of all of the recalled product under the knowledge of the U.S. Food and Drug Administration.

Taro Pharmaceuticals U.S.A. is a U.S. unit of Israel-based pharmaceutical Taro Pharmaceutical Industries Ltd.